6 edition of Viral and immunological diseases in nonhuman primates found in the catalog.
|Statement||editor, S.S. Kalter.|
|Series||Monographs in primatology ;, 2|
|Contributions||Kalter, S. S., Southwest Foundation Forum (San Antonio, Tex.)|
|LC Classifications||RC114.5 .V476 1983|
|The Physical Object|
|Pagination||xii, 265 p. ;|
|Number of Pages||265|
|LC Control Number||83005385|
TY - CHAP. T1 - Viral-vectored vaccines to control pathogenic filoviruses. AU - Mire, Chad. AU - Geisbert, Thomas. PY - /7/1. Y1 - /7/1. N2 - For more than 35 years the filoviruses, Marburg virus and Ebola virus, have caused sporadic outbreaks of hemorrhagic fever that result in severe and often fatal disease in humans and nonhuman primates. The transmembrane glycoprotein can be used to provoke a protective immune response in animal models including nonhuman primates. AB - Marburg and Ebola viruses, from the family Filoviridae, are prototype viral hemorrhagic fever pathogens that cause a fulminant hemorrhagic disease in humans and nonhuman primates.
Nonhuman primates Spillover hosts Antibody mediated immune responses to experimental viral infections Maternally derived antibody protection book that will serve as an excellent reference for scientists studying bats and their related emerging infectious viral diseases This book consists. The recent reemergence of Ebola (EBO) hemorrhagic fever (EHF) in Kikwit, Democratic Republic of the Congo (DRC), the introduction of a Philippine EBO virus (subtype Reston [EBO-R]) into a primate facility in Alice, Texas , and the ensuing press and media attention have prompted worldwide interest in the biology and public health threat of these viral pathogens.
No substantial inflammation was observed in the lungs of nonhuman primates vaccinated with μg of mRNA, and neither viral RNA nor antigen was detected at day 7 or 8 after challenge. In. Chikungunya is an infection caused by the Chikungunya virus (CHIKV). Symptoms include fever and joint pains. These typically occur two to twelve days after exposure. Other symptoms may include headache, muscle pain, joint swelling, and a rash. Symptoms usually improve within a week; however, occasionally the joint pain may last for months or years.
New species of Thalamoporella (Bryozoa)
The Never-Ending War
With Rommel in the Desert
tale of the tub
Instructors Resource Book to Accompany Understanding Reading Pro
Road to Chess Mastery
Guns Dorking Hollow
Model development and systems analysis of the Yakima River Basin
Women in the West
Poor Robins almanac, for the year 1803 ...
This is the first time an experimental COVID vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (K), or click on a page image below to browse page by : Judy A Macarthur.
Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (K), or click on a page image below to browse page by by: 2. Get this from a library. Viral and immunological diseases in nonhuman primates: proceedings of a symposium, use of nonhuman primates in exotic viral and immunological disease, held February March 3,in San Antonio, Texas.
[S S. Review of Viral and Immunological Diseases in Nonhuman Primates, edited by S.S. Kalter, Alan R. Liss, Inc, New York,pp, $ Virtually all investigators in primate research are now compelled to indicate the relevance of their studies for human health and disease issues.
With the publication of a recent Proceedings on immunological research with primates, it is possible to. Abstract. Infectious diseases and especially viral diseases of nonhuman primates have been studied since the advent of virology but have been the particular focus of attention of several groups during the past two decades [34, 37, 60, 68, ].
Here, we demonstrate that EBOVΔVP30 protects nonhuman primates against lethal infection with EBOV. Although EBOVΔVP30 is replication-incompetent, we additionally inactivated the vaccine with hydrogen peroxide; the chemically inactivated vaccine remained antigenic and protective in nonhuman primates.
Immunosuppressive disease in nonhuman primates may be caused by a number of retroviruses, including several orthoretroviruses formerly called type C and type D oncornaviruses, and several simian immunodeficiency viruses (SIVs).
The SIVs are lentiviruses closely related to human immunodeficiency virus 1 (HIV-1) and HIV Nonhuman primate (NHP) models were rapidly developed to understand the disease and to test vaccines, and these models have since provided an understanding of the immune. Zika virus (ZIKV) infection is associated with congenital defects and pregnancy loss.
Here, we found that 26% of nonhuman primates infected with Asian/American ZIKV in early gestation experienced. Thea Brabb, Ronald F. Di Giacomo, in The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents, The major focus of this chapter is the naturally occurring viral diseases of rabbits and hares.
The viral diseases of rabbits are discussed in an order based on the taxonomic groups to which the viruses belong and are independent of the order of importance of the various diseases.
Moderna’s vaccine protects monkeys against COVID, study finds This is the first time an experimental COVID vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the researchers noted.
To determine whether aging influences the severity of disease caused by A(H7N9) virus infection in nonhuman primates, we infected 7 aged (aged 20–26 years) and 6 young (aged 2–3 years) cynomolgus macaques with A/Anhui/1/ (Anhui/1) and monitored their clinical symptoms.
Three of the aged animals (nos. 1, 2, and 3) did not show any. In the study, two doses of mRNA provided protection against lung inflammation following viral challenge with SARS-CoV-2 in non-human primates at both the.
 Nonhuman primates (NHPs) are an extremely important model for critical research pertaining to human health, such as aging, viral hepatitis infection, Zika virus infection, and HIV.
This is the first time an experimental COVID vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note. A COVID vaccine that reduces viral replication in the lungs would limit disease in the individual, while reducing shedding in the upper airway would potentially.
Two doses of an experimental vaccine to prevent coronavirus disease (COVID) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
SARS-CoV-2 is the virus that causes. Two doses of mRNA provided protection against lung inflammation following viral challenge with SARS-CoV-2 in non-human primates at both the 10 µg and µg dose levels. In addition, both the 10 µg and µg dose groups demonstrated protection against viral replication in the lungs, with the µg dose also protecting against viral.
The book provides up-to-date summaries on the main systems of blood group antigens and MHC molecules in nonhuman primates. For each system, the human antigens are described and used as a. Simian Foamy Virus. Simian foamy virus (SFV) is infecting primates at high levels: 70% of primates in captivity, 97% of wild western red colobus monkeys, and between 44% and % of wild chimpanzees– SFVs have been documented in primate care workers in the United States, in hunters in Cameroon and Gabon, and in women living in rural DRC– Moreover, SFV.
Viral and Immunological Diseases in Nonhuman Primates: Monographs in Primatology, vol 2. (PMCID:PMC) Full Text Citations ; BioEntities ; Related Articles ; External Links ; J R Soc Med.
February; 77(2): – PMCID: PMC Viral and Immunological Diseases in Nonhuman Primates. Monographs in Primatology, vol 2.A licensed vaccine against Ebola virus (EBOV) remains unavailable, despite >11 deaths from the outbreak of EBOV disease in West Africa.
Past studies have shown that recombinant vaccine viruses expressing EBOV glycoprotein (GP) are able to protect nonhuman primates (NHPs) from a leth. “We believe this is the first demonstration of control of viral replication within 2 days of challenge in both the nose and lungs in nonhuman primates by a vaccine against COVID,” said.